CMHC West

May 4-5, 2018

Wynn Las Vegas

Advancing Cardiometabolic Health from East to West


Friday, May 4, 2018

6:30 - 7:00 am

Registration and Exhibits

7:10 - 8:25 am

PME Breakfast or CME Breakfast Symposium

Session I: Obesity and Lifestyle Medicine

8:35 - 8:40 am

Chair Introduction and Opening Remarks

Chair: Robert H. Eckel, MD

8:40 - 9:00 am

Bariatric Surgery: an Overview

John Magaña Morton, MD

9:00 - 9:20 am

What You Need to Know: Complications of Bariatric Surgery

Daniel H. Bessesen, MD

9:20 - 9:40 am

Cardiovascular Benefits of Bariatric Surgery

Sangeeta R. Kashyap, MD

9:40 - 10:00 am

Panel Discussion and Q&A

Chair: Robert H. Eckel, MD
Panel: Daniel H. Bessesen, MD;
John Magaña Morton, MD;
Sangeeta R. Kashyap, MD

10:05 - 10:35 am

Morning Break

10:40 - 11:10 am

Keynote Presentation
Obesity and Inflammation: What have we learned from animal models?

Alan Chait, MD

11:10 - 11:30 am

Benefits of Physical Activity and Exercise on Cardiovascular and Mental Health

Jason R. Tregellas, PhD

11:30 - 11:50 am

Navigating Weight Loss Management in Diabetic Patients with CV Risk

Ken Fujioka, MD

11:50 am - 12:10 pm

Panel Discussion and Q&A

Chair: Robert H. Eckel, MD
Panel: Ken Fujioka, MD;
Jason R. Tregellas, PhD

12:10 pm

Closing Remarks

Robert H. Eckel, MD

12:20 - 1:35 pm

PME Lunch Symposium (NON-CME)
Sponsored by Amgen, Inc.

Session II: Dyslipidemia/Atherosclerosis

1:45 - 1:50 pm

Chair Introduction

Chair: Christie M. Ballantyne, MD

1:50 - 2:10 pm

Advances in Lipid Therapy: Non-statin Drugs and New Approaches

2:10 - 2:30 pm

Familial Hypercholesterolemia: What You Need to Know

Joshua W. Knowles, MD

2:30 - 3:10 pm

Challenging Patient Cases with Q&A: Assessing Safety of More Aggressive LDL Lowering

Robert H. Eckel, MD
Christie M. Ballantyne, MD

3:15 - 3:45 pm

Afternoon Break

3:50 - 4:10 pm

Updates in Severe Hypertriglyceridemia Treatment

Sotirios Tsimikas, MD

4:10 - 4:30 pm

Navigating the Diagnosis and Treatment of Hypertriglyceridemia in Patients with High CV Risk

Karol Watson, MD

4:30 - 4:50 pm

Importance of Lifestyle Modifications in Lipid Management

Nancy Houston Miller, RN, BSN

4:50 - 5:10 pm

Integrating Evidence-Based Data and Guidelines into Clinical Practice

Yehuda Handelsman, MD

5:10 - 5:30 pm

Panel Discussion and Q&A

Chair: Christie M. Ballantyne, MD
Panel: Robert H. Eckel, MD;
Yehuda Handelsman, MD;
Nancy Houston Miller, RN, BSN;
Sotirios Tsimikas, MD;
Karol Watson, MD

5:30 pm

Closing Remarks

Chair: Christie M. Ballantyne, MD

5:35 - 6:35 pm

Networking Reception

6:45 - 8:00 pm

PME Dinner Symposium (NON-CME)
Sponsored by Akcea Therapeutics

Saturday, May 5, 2018

7:00 - 7:30 am

Registration and Exhibits

7:40 - 8:55 am

PME Breakfast or CME Breakfast Symposium

Session III: Heart Failure And Hypertension

9:05 - 9:10 am

Chair Introduction

Chair: Clyde W. Yancy, MD

9:10 - 9:35 am

I. Updates in Hypertension: New Blood Pressure Guidelines

Matthew R. Weir, MD

9:35 - 9:55 am

II. Challenging Patient Case: Best Approach to Treatment in Patients with CKD, Hypertension, and T2DM

Matthew R. Weir, MD

9:55 - 10:15 am

Panel Discussion and Q&A

Chair: Clyde W. Yancy, MD
Panel: Matthew R. Weir, MD

10:20 - 10:50 am

Morning Break

10:55 - 11:20 am

I. Risk of Heart Failure in Diabetic Patients

Yehuda Handelsman, MD

11:20 - 11:35 am

II. Challenging Patient Case: Controlling the of Risk Factors for Heart Failure in Patients with Diabetes

Yehuda Handelsman, MD

11:35 am - 12:00 pm

I. Approaches to Blood Pressure Control in Heart Failure

Clyde W. Yancy, MD

12:00 - 12:20 pm

II. Integrating BP Control Approaches in A Challenging Heart Failure Patient Case

Clyde W. Yancy, MD

12:20 - 12:40 pm

Panel Discussion and Q&A

Chair: Clyde W. Yancy, MD
Panel: Yehuda Handelsman, MD

12:40 pm

Closing Remarks

Chair: Clyde W. Yancy, MD

12:50 - 2:05 pm

CME Lunch Symposium
Updates in Inflammation and Secondary CVD Prevention
Supported by an educational grant from Novartis Pharmaceuticals Corporation

Session IV: Diabetes Management

2:15 - 2:20 pm

Chair Introduction

Chair: Jay S. Skyler, MD

2:20 - 2:50 pm

Updates on CVOTs: Completed and Ongoing

Sanjay Kaul, MD

2:50 - 3:20 pm

SGLT2 Inhibitors: MOAs, Benefits, Outcomes, and Class Effect

Leigh Perreault, MD

3:20 - 3:50 pm

GLP1 Agonists: MOAs, Benefits, Outcomes, and Differences Between Trials

3:55 - 4:25 pm

Afternoon Break

4:30 - 5:00 pm

Combination Therapy for T2DM: Which Drugs for Which Patients?

Athena Philis-Tsimikas, MD

5:00 - 5:25 pm

Challenging Patient Cases: Are the Guidelines Still Relevant in 2018?

Chair: Jay S. Skyler, MD
Presenters: Robert H. Eckel, MD;
Sanjay Kaul, MD;
Steven E. Kahn MB, ChB;
Leigh Perreault, MD;
Athena Philis-Tsimikas, MD

5:25 - 5:45 pm

Panel Discussion and Q&A

Chair: Jay S. Skyler, MD
Panel: Robert H. Eckel, MD;
Sanjay Kaul, MD;
Steven E. Kahn MB, ChB;
Leigh Perreault, MD;
Athena Philis-Tsimikas, MD

5:45 - 5:50 pm

Meeting Closing Remarks

Chair: Jay S. Skyler, MD